Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Alemtuzumab)
3,547 results
  • Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. [Journal Article]
    Clin Exp Med. 2023 Jan 15 [Online ahead of print]Kazakou P, Tzanetakos D, … Zapanti E
  • Autoimmune thyroid disease (AITD) is the most common adverse effect in alemtuzumab (ALZ) treated relapsing-remitting (RR) multiple sclerosis (MS) patients. The objective of this prospective study was to analyze the occurrence, timing of onset, clinical course, and laboratory characteristics of AITD post-ALZ. We evaluated 35 RRMS patients treated with ALZ at a single academic MS center; clinical a…
  • Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. [Journal Article]
    J Clin Oncol. 2023 Jan 09 [Online ahead of print]Eapen M, Brazauskas R, … Horowitz MM
  • CONCLUSIONS: Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.
  • Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. [Journal Article]
    Mult Scler J Exp Transl Clin. 2023 Jan-Mar; 9(1):20552173221142741.Dayan CM, Lecumberri B, … Senior PA
  • CONCLUSIONS: Adjudicated thyroid events occurring over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients were primarily autoimmune. Thyroid events were considered manageable and did not affect disease course. Thyroid autoimmunity is a common but manageable adverse event in alemtuzumab-treated relapsing multiple sclerosis patients.ClinicalTrials.gov Registration Numbers: CARE-MS I (NCT00530348); CARE-MS II (NCT00548405); CARE-MS Extension (NCT00930553).
  • Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. [Journal Article]
    Br J Clin Pharmacol. 2022 Nov 21 [Online ahead of print]Zwart TC, Bezstarosti S, … Moes DJAR
  • CONCLUSIONS: Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalised treatment strategy. Lean bodyweight-adjusted dosing poses an option for individualised dosing, but further evaluation of its potential clinical benefit is warranted.
  • Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature. [Review]
    Clin Rheumatol. 2023 Feb; 42(2):339-357.Ak T, Durmus RB, Onel M
  • Cutaneo us vasculitis (CV) has a broad spectrum of etiologies, and drugs are one of the main culprits. With the increasing use of targeted therapies in medicine, especially in rheumatology and oncology, the number of CV cases reported due to these drugs has increased. Therefore, the recognition and treatment of CV associated with targeted agents have become more and more important. In the literat…
  • High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. [Review]
    CNS Drugs. 2022 12; 36(12):1285-1299.Freeman L, Longbrake EE, … Vollmer T
  • There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensus guidelines offering differing recommendations, there is broad heterogeneity in how the DM…
  • A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis. [Review]
    Ann Pharmacother. 2022 Nov 09 [Online ahead of print]Summerlin J, Wells DA, … Halford Z
  • CONCLUSIONS: Improvements in diagnostic methods and novel immunosuppressive treatment strategies, including noncytotoxic immunochemotherapy, have transformed the therapeutic landscape. Unfortunately, many unanswered questions remain. Additional studies are required to optimize dosing, schedules, treatment sequences, and indications for novel treatment options.
New Search Next